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Abstract 16 
Patients with acromegaly have a higher prevalence of vertebral fractures despite normal bone 17 
mineral density (BMD), suggesting that GH overexpression has adverse effects on skeletal 18 
architecture and strength. We used giant bovine GH (bGH) transgenic mice to analyze the effects of 19 
high serum GH levels on BMD, architecture, and mechanical strength. Five-month-old hemizygous 20 
male bGH mice were compared with age- and sex-matched nontransgenic littermates controls (NT; 21 
n=16/group). Bone architecture and BMD were analyzed in tibia and lumbar vertebrae using 22 
microcomputed tomography. Femora were tested to failure using three-point bending and bone 23 
cellular activity determined by bone histomorphometry. bGH transgenic mice displayed significant 24 
increases in body weight and bone lengths. bGH tibia showed decreases in trabecular bone volume 25 
fraction, thickness, and number compared with NT ones, whereas trabecular pattern factor and 26 
structure model index were significantly increased, indicating deterioration in bone structure. 27 
Although cortical tissue perimeter was increased in transgenic mice, cortical thickness was reduced. 28 
bGH mice showed similar trabecular BMD but reduced trabecular thickness in lumbar vertebra 29 
relative to controls. Cortical BMD and thickness were significantly reduced in bGH lumbar vertebra. 30 
Mechanical testing of femora confirmed that bGH femora have decreased intrinsic mechanical 31 
properties compared with NT ones. Bone turnover is increased in favor of bone resorption in bGH 32 
tibia and vertebra compared with controls, and serum PTH levels is also enhanced in bGH mice. 33 
These data collectively suggest that high serum GH levels negatively affect bone architecture and 34 
quality at multiple skeletal sites.  35 
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Introduction 36 
GH is a peptide hormone secreted by the anterior pituitary gland, which has catabolic and 37 
anabolic actions on many organ systems. In the skeleton, it facilitates linear bone growth by causing 38 
chondrocyte proliferation at the epiphyseal cartilage in the growth plate region (1,–3). GH also has 39 
numerous metabolic functions regulating carbohydrate and lipid metabolism (4). It induces 40 
intracellular signals through the GH receptor (GHR), a predimerized cytokine receptor signaling 41 
through the Janus kinase (JAK)-signal transducer and activator of transcription pathway (STAT) (5). 42 
Many of the growth-promoting actions of GH are mediated by IGF-1, which is synthesized in most 43 
peripheral tissues, with liver synthesis contributing primarily to circulating IGF-1 levels (1). Both GH 44 
and IGF-1 are anabolic hormones for the skeleton and are involved in the stimulation of bone 45 
formation (1, 6). Although they have overlapping effects, GH and IGF-1 also have distinct effects on 46 
skeletal development, bone growth, and fracture risk (7). 47 
The importance of GH in the regulation of bone growth is best seen in patients with GH 48 
deficiency (GHD) or GH excess (8, 9). Patients with GHD have a low bone turnover, whereas excess 49 
GH, usually due to a GH-secreting pituitary tumor causing acromegaly, is associated with increased 50 
bone turnover (9, 10). Although patients with acromegaly have characteristically enlarged bones and 51 
excess cortical bone and osteophytes, clinical reports and experimental studies have shown 52 
inconsistent data on bone mineral density (BMD) and, paradoxically, a number of studies suggested 53 
increased fracture risk in these patients (11,–16). The clinical picture regarding bone is complicated 54 
by the fact that patients with acromegaly often have hypogonadism due to excess prolactin 55 
secretion and/or reduced gonadotropins due to tumor pressure effects. In active acromegaly, high 56 
GH levels are associated with increased cortical BMD, whereas the effects on trabecular BMD are 57 
more variable (17,–20). In addition, fracture risk in acromegaly was shown to be either associated 58 
with BMD or independent of it, suggesting that BMD alone is not a sufficient indicator of fracture 59 
risk (12,–14, 21). The effects of an excess GH on bone architecture and strength are still unclear. 60 
Bone fracture risk is dependent on the overall bone strength, which itself depends on bone 61 
structural and material properties, both of which are affected by bone turnover (22). Structural 62 
properties of bone include its geometry and architecture (23), whereas its material properties 63 
depend mainly on bone mineral and collagen contents that are affected by the rate of bone 64 
remodeling (24). 65 
Several transgenic animal models have been developed to study the effects of GH on bone. 66 
Transgenic expression of bovine GH (bGH) or rat GH in mice is now commonly used to study GH 67 
physiology, and GH is often fused with a transcriptional regulatory element such as the 68 
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metallothionein promoter/enhancer whose expression is constitutive (25,–27). Also, 69 
supraphysiological levels of GH are usually found in these GH transgenic mice (25). Although several 70 
studies have shown changes in bone growth, turnover and BMD in transgenic mice overexpressing 71 
GH (26, 28,–30), there has been no extensive characterization of the three-dimensional bone 72 
microarchitecture in cortical and trabecular compartments in relation with bone strength in those 73 
mice. 74 
The aim of this study was to examine whether the observed higher prevalence of vertebral 75 
fractures in acromegaly patients (11,–15) could be explained by a compromised bone architecture 76 
and strength. We used giant bGH transgenic mice to examine the effects of high serum GH and IGF-1 77 
levels on BMD, on vertebra and tibia trabecular, and cortical bone architecture as well as on 78 
mechanical strength in comparison with nontransgenic littermates control mice of the same age and 79 
sex. Moreover, this work served to ascertain the potential of this transgenic mouse model for 80 
further studies of the skeletal changes associated with acromegaly. 81 
Materials and methods 82 
Animals 83 
bGH transgenic mice and nontransgenic littermates controls (NT) were generated as 84 
described by Berryman et al (27). Briefly, bGH transgenic mice were generated using a 85 
metallothionein transcriptional regulatory element linked to the first exon and intron of the bGH 86 
cDNA. C57BL/6J embryos were injected with this construct, and the mice were maintained in the 87 
genetic background. In our study, we used 5-month-old male mice and a total of 16 mice for each 88 
genotype (NT and bGH) were analyzed. Blood was collected immediately after killing for hormone 89 
measurements. The left tibiae and femora as well as lumbar vertebrae of 16 mice/group were 90 
dissected, fixed in 10% neural-buffered formalin for 24–72 hours, and stored in 70% ethanol at 4°C 91 
for microcomputed tomography (micro-CT) analysis of BMD and bone architecture. Right femora 92 
were dissected and stored at −20°C for mechanical testing. To label bone-forming surfaces in 93 
trabecular bone, mice (nine per group) were injected ip with calcein (Sigma-Aldrich) on day 8 and 94 
alizarin red complexone (Sigma-Aldrich) on day 3, prior to euthanasia. Right tibiae and L4 vertebrae 95 
were collected from these mice for bone histomorphometry analysis. 96 
Micro-CT analysis of tibiae and vertebrae 97 
Tibiae were scanned using high resolution (5 μm pixel size) micro-CT (Skyscan 1172) at x-ray 98 
energy settings of 50 kV and 200 μA, using a 0.5 mm aluminum filter. Skyscan software was used for 99 
computed tomography reconstructions (NRecon version 1.6.4.1) and bone histomorphometric 100 
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analyses in two and three dimensions (CT-Analyzer, version 1.13.5.1+) (31). The trabecular bone 101 
analysis in tibiae was made in the proximal metaphysis. A reference point was chosen that 102 
corresponds to the appearance of secondary spongiosa, and 50 tomograms below this reference 103 
point were left unanalyzed before the analysis was made on 250 tomograms. The cortical bone was 104 
excluded by operator-drawn regions of interest, and three-dimensional algorithms were used to 105 
determine the relevant parameters including bone volume fraction [expressed as percentage of 106 
bone volume (BV) over tissue volume (TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), 107 
trabecular separation (Tb.Sp), structure model index (SMI), trabecular bone pattern factor (TBPf), 108 
and the degree of anisotropy (DA)]. Analysis of cortical bone was performed along a 0.49-mm-long 109 
segment (or 100 tomograms) at 37% and 50% of the full length of the tibia calculated from its 110 
proximal end. For analysis of the cortical bone compartment, two-dimensional computation was 111 
used, and parameters were determined for each of the 100 tomograms and then averaged. 112 
Parameters included the following: total cross-sectional area (Tt.Ar), cortical bone area (Ct.Ar), 113 
cortical bone perimeter (Ct.Pm), cross-sectional thickness (Ct.Th), and medullary area (Ma.Ar). 114 
Cortical and trabecular bone architecture was also evaluated in L4 and L5 vertebrae using the same 115 
settings as for tibiae. The region of interest included the whole body of vertebrae. 116 
BMD measurement in vertebrae 117 
BMD analysis in lumbar vertebrae (L4 and L5) was performed with Skyscan software (CT-118 
Analyzer, version 1.13.5.1+). BMD is defined as the volumetric density of calcium hydroxyapatite in 119 
grams per cubic centimeter. Two Skyscan-supplied bone phantoms with known BMD values of 0.25 120 
and 0.75 g/cm3 calcium hydroxyapatite were scanned and reconstructed with the same methods 121 
and parameters as the vertebrae. 122 
Mechanical testing of femora 123 
Femora were excised immediately after the animals were killed, individually stored in saline 124 
soaked gauze, and frozen at −20°C. Immediately before testing, they were thawed and immersed in 125 
saline solution during the whole analysis. Three-point bending test of femora from NT and bGH mice 126 
was performed as previously described (32). This test allows the calculation of a number of bone 127 
mechanical properties, including resistance to bending under load (stiffness), the maximum load 128 
that a bone can sustain prior to breaking (maximum load), and the amount of energy the bone can 129 
absorb before failure (toughness). Calculations of bone mechanical properties included Young's 130 
modulus, a measure of the resistance of a material to elastic deformation under load, and ultimate 131 
stress, which is the maximum load normalized by the geometry of the bone midshaft. 132 
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Bone histomorphometry 133 
Tibia were fixed in 10% neutral-buffered formalin for 24 hours, dehydrated, and embedded 134 
in methyl metacrylate at low temperature to preserve enzymatic activity (33). Unstained 8-μm-thick 135 
sections were used for fluorescence microscopy to assess mineral apposition rate (MAR; 136 
micrometers per day). Mineralizing surfaces were expressed as alizarin red-labeled surfaces per 137 
bone surfaces (MS/BS; percentage), and the bone formation rate was calculated as MS/BS × MAR 138 
[bone formation rate per bone surface (BFR/BS); cubic micrometers per square micrometer per day)] 139 
(34). Alternatively, sections were stained for tartrate-resistant acid phosphatase (TRAP) (Leucognost 140 
SP; Merck) and counterstained with Weigert hematoxylin solution. Histomorphometric parameters 141 
were measured on the trabecular bone of the metaphysis on a region of interest consisting of 2 mm 142 
width below the growth plate after Goldner's trichrome staining of sections. Measurements were 143 
performed using image analysis software (Tablet' measure; Explora Nova). Histomorphometric 144 
parameters were reported in accordance with the American Society for Bone and Mineral Research 145 
Committee nomenclature (35). L4 vertebrae preserved at 4° after micro-CT analysis were processed 146 
in methyl metacrylate as described above and used to assess mineral and apposition rates. TRAP 147 
staining was not possible in those vertebrae due to the loss of enzymatic activity. 148 
PTH measurement 149 
Serum PTH levels were measured using a commercial mouse PTH 1–84 ELISA kit (Immutopics). 150 
Statistical analysis 151 
The results were presented as mean ± SD. Comparisons between groups for all data were 152 
performed using an unpaired t test (two tailed). Differences were considered significant at P < .05. 153 
All statistical analyses were performed using GraphPad Prism Software (GraphPad Software Inc). 154 
Linear regression analysis with adjustment for body weight was performed using SPSS. 155 
 156 
Results 157 
bGH mice have increased body weight and bone length compared with their littermate controls 158 
Five-month-old hemizygous male bGH mice were compared with age- and sex-matched NT 159 
controls (n = 16/group). As expected, bGH transgenic mice displayed significant increases in body 160 
weight (Figure 1A). Bone lengths of tibia, femora, and lumbar vertebra (total length of L4 and L5) 161 
were measured using micro-CT. All bones were consistently longer in bGH mice compared with NT 162 
mice (Figure 1, B–D). 163 
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bGH mice have lower trabecular bone volume fraction in the tibial metaphysis compared with their 164 
littermate controls 165 
Using micro-CT imaging, we found that the trabecular bone volume fraction (BV/TV) was 166 
significantly reduced in the bGH mice compared with the NT mice, indicating that bGH mice have 167 
low bone mass. This was the case when results were expressed both as direct measurements or 168 
when they were adjusted for bone length differences between NT and bGH mice (Table 1). The bone 169 
structural analysis showed that the lower BV/TV was due to a reduction in both trabecular thickness 170 
and number, although the reduction in trabecular thickness was more highly significant (Table 1). 171 
The significant decrease in BV/TV in bGH mice was confirmed by histomorphometry measurements 172 
(Table 2). The significant increases in trabecular pattern factor and SMI in bGH mice indicate less 173 
intertrabecular connectivity, suggesting deterioration of trabecular bone microarchitecture in those 174 
mice (Table 1). The degree of anisotropy was significantly decreased in bGH mice compared with NT 175 
mice (Table 1), indicating increased isotropic structure in bGH mice. 176 
bGH mice have increased bone perimeter but lower cortical bone thickness in tibiae compared with 177 
their littermate controls 178 
Cortical bone architecture was also analyzed at 37% and 50% of tibia length from its 179 
proximal end. Similar data were obtained at both lengths, and Table 1 illustrates the results at 37% 180 
of tibia length. Although cortical bone area was similar in bGH and NT mice, total cross-sectional 181 
area, cortical bone perimeter, and medullary area were increased and cross-sectional thickness 182 
significantly decreased in bGH mice compared with NT mice (Table 1), suggesting that bone size and 183 
geometry are different in bGH mice. All these differences remained highly significant after correction 184 
for tibiae length. In contrast, only the decrease in cortical thickness in bGH mice remained significant 185 
after adjustment for body weight. 186 
bGH mice have decreased bone cortical mineral density and changes in trabecular and cortical 187 
structural parameters in vertebrae compared with their littermate controls 188 
BMD was evaluated in fourth and fifth lumbar vertebrae (L4 and L5). Similar results were 189 
obtained for both vertebrae, and we have illustrated the results obtained on the fifth lumbar 190 
vertebrae. We did not measure significant differences in the BMD of the trabecular compartment in 191 
the vertebrae between bGH and NT mice (Figure 2A), whereas the BMD in the cortical compartment 192 
was significantly decreased in bGH vertebrae compared with NT ones (Figure 2B). BV/TV was not 193 
different in bGH and NT mice vertebrae, except when adjusted for bone length (Table 3). Trabecular 194 
thickness was significantly decreased in bGH vertebrae compared with the NT group, even after 195 
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adjustment for length and body weight, although histomorphometry data showed only a trend for a 196 
decrease (Tables 3 and and4).4). Other trabecular parameters were not consistently affected. 197 
Significant differences were also observed in cortical bone because L4 and L5 vertebrae in bGH 198 
group showed increased bone cortical area but decreased cortical thickness (Table 3). However, only 199 
cortical thickness remained significant after correction for both body weight and vertebrae length. 200 
bGH mice have decreased mechanical strength in tibiae compared with their littermate controls 201 
To investigate bone mechanical properties of bGH mice, their femurs were removed at 5 202 
months and subjected to three-point bending tests. Data on the mechanical strength of the femurs 203 
are shown in Figure 3. Compared with the NT group, bGH had weaker bones, as illustrated by 204 
significantly reduced ultimate stress (Figure 3A) and Young's modulus (Figure 3B). There was also a 205 
trend for a reduced stiffness in bGH mice compared with NT mice, close to significance (Figure 3C). 206 
bGH mice have increased bone remodeling compared with their littermate controls 207 
To determine the cause of the low trabecular bone mass in bGH mice, we examined bone 208 
cellular activities in the tibia of those mice, using bone histomorphometry. Histomorphometric 209 
assessment confirmed our micro-CT findings that trabecular BV/TV in tibial metaphysis is 210 
significantly decreased in bGH compared with NT mice (Figure 4A and Table 2). Analysis of 211 
mineralizing apposition and bone formation rates using double-fluorescence labeling showed that 212 
bGH mice have a higher bone formation rate than NT mice (Figure 4C). MAR was significantly 213 
increased (Table 2). The percentage of TRAP-positive surfaces (representing resorption surfaces) was 214 
also significantly higher in the bGH mice compared with NT mice (Figure 4B). These results indicate 215 
that the bGH mice have a higher trabecular bone turnover compared with their littermates controls, 216 
which is associated with a low trabecular bone mass phenotype. The increased bone formation rate 217 
in bGH mice compared with their littermate controls was also observed in vertebrae (Table 4). We 218 
also measured serum PTH levels in our mice, and we found significantly increased PTH levels in 5-219 
month-old male bGH mice compared with littermate controls (Figure 4D). 220 
 221 
Discussion 222 
This study shows that bGH mice with elevated serum GH levels have compromised bone 223 
architecture, characteristic that often mimics the skeletal changes experienced by acromegaly 224 
patients. The use of bGH mice is a valuable model for the study of skeletal changes in response to 225 
excess GH that occur in acromegaly patients. The advantage of this experimental mouse model is 226 
that there is no associated hypogonadism (36), so it is easier to decipher the skeletal effects of 227 
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excess GH than in acromegaly patients. There is, however, a major difference between the bGH 228 
mouse model and acromegaly patients as in patients' overexpression of GH usually occurs after 229 
epiphyseal closure. Conversely, overexpression of GH in bGH mice occurs in utero and through adult 230 
life. Thus, it is possible that the temporal control of GH overexpression has implications on bone 231 
regulation. 232 
Our works shows that bGH mice have significant increases in total body weight and in bone 233 
lengths. This supports previous studies that demonstrated that human GH and bGH transgenic mice 234 
are larger and exhibit disproportionate skeletal gigantism (28,–30, 37, 38). Bone sizes are increased 235 
in bGH mice (30), and treatment of growing rats with human GH rats leads to an increase in bone 236 
size (39). Elevated levels of GH appear to be the main cause for gigantism in those mice rather than 237 
an increase in mechanical loading as a result of increased body weight (40). 238 
Bone architecture in bGH mice has been poorly studied. GH has complex effects on bone 239 
that vary, depending on the skeletal compartments and different sites. Using high-resolution micro-240 
CT, we found that bGH mice have altered cortical and trabecular bone architecture in long bones. 241 
Analysis of trabecular bone in tibia shows that despite an increase in bone length, bGH mice have 242 
significantly lower bone volume fraction (BV/TV) and trabecular number and thickness than 243 
littermate controls, indicating a low trabecular bone mass in those mice. In addition, measurements 244 
of parameters reflecting the structure and the geometry of trabecular bone clearly demonstrate less 245 
intertrabecular connectivity and more rod-like structures in trabecular bone of bGH mice, 246 
representing a deterioration of trabecular bone quality that is similar to what is observed with aging 247 
and in osteoporosis (41) and in agreement with most clinical studies (20). Cortical bone thickness 248 
was also significantly decreased in tibia despite increases in total cross-sectional area, cortical tissue 249 
perimeter, and medullary area, reflecting the bigger tibia in bGH mice. Previous micro-CT analysis of 250 
GH transgenic mice did not show any major change in trabecular bone volume fraction in male mice. 251 
In contrast, female transgenic mice showed an increase in trabecular bone fraction volume in 252 
femora (29). This discrepancy could be due to a different mouse genetic background and/or the age 253 
of the mice because the transgenic mice used in our study are older (5 mo vs 3 mo in the previous 254 
study). Our resolution for micro-CT analysis of bone architecture was also 10 times higher than that 255 
used in the former study (29). 256 
Because there is an increased prevalence of vertebral fractures in acromegaly patients (12), 257 
we also examined bone architecture and BMD in vertebrae of bGH mice. Surprisingly, there were no 258 
significant changes in trabecular BMD and bone volume fraction in L4 and L5 vertebrae of bGH mice 259 
compared with controls but a decrease in trabecular thickness. Cortical bone was more significantly 260 
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affected because bGH mice have significantly lower cortical BMD and cortical thickness in the lumbar 261 
vertebrae than their controls. Although cortical bone density was also previously shown to be 262 
significantly lower in femora of bGH transgenic mice (30), these results in mouse models conflict 263 
with clinical records whereby elevated GH levels are often linked to increased cortical BMD in 264 
humans (1, 19, 20, 42). Clinical data are, however, mostly based on BMD measurements by dual-265 
energy X-ray absorptiometry, which cannot discriminate between cortical and trabecular 266 
compartments, in contrast to micro-CT or peripheral quantitative computed tomography (pQCT). 267 
The view of increased cortical BMD in patients with active acromegaly is supported by the fact that 268 
these patients have an increase in BMD at the forearm and/or femoral neck, two sites at which 269 
cortical bone is the main determinant of bone strength, whereas BMD is less affected at the lumbar 270 
spine, a site at which trabecular bone is dominant (19, 43, 44). This was corroborated in a clinical 271 
study using high-resolution pQCT, which showed higher cortical density in the distal tibia in patients 272 
with active acromegaly compared with controlled acromegaly (20), suggesting that high resolution 273 
pQCT should allow better in vivo assessments of the bone architecture in acromegaly patients in the 274 
future. 275 
Interestingly, studies conducted in childhood- and adult-onset GHD have also shown 276 
reduced cortical bone (45) and GH therapy in GHD patients seems to have a greater effect on cortical 277 
than on trabecular bone (46). Our data support previous conclusions demonstrating that the skeletal 278 
effects of GH depend on the compartment and the site analyzed, and this may be due to changes in 279 
vascular supply, response to sex steroids, and/or mechanical loading (19). We used only males in our 280 
study to restrict the differences in cortical density between sexes. We analyzed bone architecture at 281 
two sites with a very different ratio in cortical and trabecular bone but that are also subject to 282 
different loading environments. We therefore cannot exclude that the differences in bone 283 
architecture between bGH mice tibiae and vertebrae depend on mechanical sensitivity to loading, 284 
which is essential for the maintenance of the skeleton in both humans and animals. Previous studies 285 
have shown that the GH/IGF-1 signaling pathway is regulated by in vivo mechanical loading (47). 286 
At all sites examined, our data suggest a deterioration of bone architecture. This was 287 
confirmed by the decreased intrinsic material properties of femora of bGH mice, leading to a 288 
reduction in bone strength, which may explain the higher rate of fractures in acromegaly patients. 289 
Decreased trabecular bone biomechanical competence was also observed in acromegaly patients 290 
(48). Interestingly, it was shown that local production of human GH in osteoblasts in a model of 291 
transgenic mice induces bone growth as expected but impaired the bones mechanical properties 292 
(49). In contrast, erythroid-specific expression of human GH leads to bones with high bone density 293 
and increased biomechanical properties (50). This suggests that localized GH expression could have 294 
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opposing effect to global GH expression as observed in our study. In models of GHD, bone 295 
mechanical properties are also not always rescued with GH treatment (51). It is, however, puzzling 296 
that acromegalic patients have a higher prevalence of vertebral fractures because our data suggest 297 
that trabecular architecture in bGH vertebrae is less deteriorated than in tibiae. 298 
The cortex also contributes to a significant part of vertebral bone strength (52) and other 299 
bone quality parameters, such as collagen content, and morphology may play a role. It is also 300 
important to point out that the spine in the mouse is not a good model of the spine in humans 301 
because it has almost no load bearing. Bone strength depends on bone morphology and composition 302 
that can be associated with changes in bone turnover rate. Our results indicate that bone turnover is 303 
largely increased in the trabecular bone of adult bGH mice tibia. We also found an increase in the 304 
number of mineralizing surfaces and osteoclasts on bone surfaces, suggesting that bone cell 305 
numbers and activities are both stimulated in bGH mice compared with controls. To our knowledge, 306 
this is the first demonstration of accelerated bone turnover in favor of bone resorption in the 307 
skeleton of bGH mice, and this may explain the deterioration of bone mechanical strength in these 308 
mice. Bone turnover markers in acromegaly patients are also increased (19) and GH treatment is 309 
effective in enhancing bone turnover (46, 53, 54). The increased bone turnover in bGH mice suggests 310 
that the deterioration of bone architecture observed in those mice is not the consequence of 311 
changes occurring during bone development that can affect bone architecture later in life. The 312 
increase in cortical perimeter together with the decrease in cortical thickness observed in bGH mice 313 
suggest that endosteal bone resorption and periosteal bone formation are both enhanced, which 314 
explains the increase in bone size. Interestingly, we found a similar increased bone formation rate in 315 
the vertebral trabecular bone of bGH mice compared with controls, suggesting that bone cellular 316 
activities are also stimulated in vertebrae, although this needs to be confirmed in case of osteoclast 317 
activity. 318 
The mechanisms leading to the enhanced bone turnover in bGH mice whose net balance is 319 
bone resorption is yet unclear. Our data show increased PTH levels in bGH mice, which could 320 
contribute to this greater bone turnover (55). GH transgenic mice have also hyperinsulinemia 321 
despite euglycemia (56). Other possible mechanisms include stimulation by GH and IGF-1 of 322 
proinflammatory cytokines that may promote osteoclastogenesis (57). A very exciting future aspect 323 
of this work will be to determine which direct or indirect signaling pathways link the excess GH in 324 
our mouse model to these deleterious effects on bone. GHR affects many signaling pathways, the 325 
major one being the JAK/STAT but additional independent pathways have been identified (58). 326 
Among the pathways affected by GHR activation and JAK2 are the MAPK and phosphatidylinositol 3-327 
kinase/Akt pathways, which play crucial roles in the differentiation, function, and survival of bone 328 
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cells (59). GH also regulates IGF-1 expression that has direct effects on bone via IGF-1 receptor and 329 
downstream signaling cascades critical for bone cell survival and metabolism (60). It is also possible 330 
that in our mouse model, the high GH tone may lead to feedback inhibition. Recent studies have 331 
indicated that GHR activation induces suppression of cytokine signaling (SOCS) proteins, which in 332 
turn inhibit GH signaling through a negative feedback mechanism. SOCS play important roles in 333 
skeletal development and osteoclastogenesis (61). 334 
In conclusion, our data collectively indicate that elevated serum GH levels have negative 335 
effects on bone architecture and quality in male mice. Combining, for the first time, high-resolution 336 
micro-CT measurements of skeletal architecture in trabecular and cortical compartments, bone 337 
mechanical testing, and quantification of bone cellular activities, we show that bGH mice display 338 
characteristics of the skeletal changes observed in acromegaly patients, which vary according to the 339 
skeletal site. Our study is limited by the fact that we have only analyzed males and only at one 340 
particular time point; therefore, we cannot exclude that bGH female mice may behave differently 341 
because the skeletal effects of GH may be influenced by sex steroids and mechanical loading. It, 342 
however, supports the notion that bone strength is decreased in acromegaly patients and that this 343 
may not always be reflected in the measurement of BMD. The inability of BMD to predict fracture 344 
risk in acromegaly patients is also true in diabetic patients (62) and clearly demonstrates the need 345 
for a better understanding of factors affecting bone quality in patients with altered GH and IGF-1 346 
metabolism. 347 
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Abbreviations 353 
BFR/BS: bone formation rate per bone surface 354 
bGH: bovine GH 355 
BMD: bone mineral density 356 
BV: bone volume 357 
Ct.Ar: cortical bone area 358 
Ct.Pm: cortical bone perimeter 359 
Ct.Th: cross-sectional thickness 360 
DA: degree of anisotropy 361 
GHD: GH deficiency 362 
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GHR: GH receptor 363 
JAK: Janus kinase 364 
Ma.Ar: medullary area 365 
MAR: mineral apposition rate 366 
micro-CT: microcomputed tomography 367 
MS/BS: mineralizing surfaces per bone surface 368 
NT: nontransgenic 369 
pQCT: peripheral quantitative computed tomography 370 
SMI: structure model index 371 
STAT: signal transducer and activator of transcription 372 
Tb.N: trabecular number 373 
Tb.Sp: trabecular separation 374 
Tb.Thtrabecular thickness 375 
TBPf: trabecular bone pattern factor 376 
TRAP: tartrate-resistant acid phosphatase 377 
Tt.Ar: total cross-sectional area 378 
TV: tissue volume 379 
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Figures and Tables 562 
 563 
 564 
 565 
Figure 1: bGH mice have increased body weights and bone lengths. 566 
 567 
NT and bGH mice were weighed at 5 months of age and lengths of tibiae, femora, and lumbar 568 
vertebrae measured using micro-CT. Body weights (A) and lengths of tibiae (B), femora (C), and 569 
vertebrae (combined L4 and L5) (D) of bGH and NT mice are shown. Values are mean ± SD of n = 16 570 
mice/group. ****, P < .0001 NT vs bGH mice.  571 
19 
 
 572 
 573 
Figure 2: bGH mice have decreased cortical BMD but not trabecular BMD in vertebrae. 574 
 575 
Cortical and trabecular BMD were assessed by micro-CT in lumbar vertebrae L5 vertebral body from 576 
NT and bGH mice aged 5 months. L5 vertebra vertebral body trabecular BMD (A) and L5 vertebra 577 
vertebral body cortical BMD (B) in bGH and NT mice. Bars represent mean ± SD of nine mice per 578 
group. ****, P < .0001 NT vs bGH mice. Tb.BMD, trabecular BMD; Ct.BMD, cortical BMD. 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
Figure 3: Mechanical testing (three point bending) of femora from bGH and NT mice. 589 
Biomechanical properties of the excised mouse femurs in NT and bGH mice aged 5 months using the 590 
three-point bending test, which tested for ultimate stress (A), Young's modulus (B), and stiffness (C). 591 
Bars represent mean ± SD of six mice per group. *, P < .05, **, P < .001 NT vs bGH mice. 592 
 593 
 594 
 595 
 596 
 597 
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Table 1: Trabecular and Cortical Bone Parameters in Tibiae of NT and bGH Mice Aged 5 Months 598 
 
 
NT Mice bGH 
Mice 
Results Expressed as a Ratio of Tibia Length 
(×100) 
NT Mice bGH Mice 
BV/TV, 
% 
5.430 ± 
0.647 
3.061 ± 
0.408a 
30.802 ± 10.304 15.685 ± 6.667b 
Tb.N, 
1/mm 
1.640 ± 
0.245 
1.114 ± 
0.155c 
9.304 ± 3.980 5.706 ± 2.382c 
Tb.Th, 
mm 
0.035 ± 
0.002 
0.028 ± 
0.001b 
0.201 ± 0.035 0.144 ± 0.015b 
Tb.Sp, 
mm 
0.373 ± 
0.038 
0.391 ± 
0.039 
2.115 ± 0.815 2.016 ± 0.760 
TBPf, 
1/mm 
8.873 ± 
4.373 
31.13 ± 
3.835b 
50.220 ± 70.117 160.118 ± 66.80b 
SMI 1.208 ± 
0.133 
1.785 ± 
0.105a 
6.844 ± 2.521 9.189 ± 1.815a 
DA 2.117 ± 
0.062 
1.793 ± 
0.063a 
12.006 ± 1.103 9.211 ± 1.034d 
Tt.Ar, 
mm2 
1.343 ± 
0.036 
1.826 ± 
0.101b 
7.608 ± 0.527 9.434 ± 1.149a (N) 
Ct.Ar, 
mm2 
0.781 ± 
0.021 
0.793 ± 
0.031 
4.427 ± 0.296 4.107 ± 0.386 
Ct.Pm, 
mm 
11.87 ± 
0.315 
16.15 ± 
0.743d 
67.266 ± 5.165 83.528 ± 8.470a (N) 
Ct.Th, 
mm 
0.131 ± 
0.002 
0.098 ± 
0.002d 
0.746 ± 0.023 0.512 ± 0.043d 
Ma.Ar, 
mm2 
0.561 ± 
0.017 
1.032 ± 
0.074d 
3.180 ± 0.241 5.326 ± 0.861d (N) 
 599 
Abbreviation: N, nonsignificant after adjustment by body weight. 600 
Results are mean ± SD 16 mice/group. 601 
aP < .01, vs NT mice. 602 
bP < .001, vs NT mice. 603 
cP < .05, vs NT mice. 604 
dP < .0001 vs NT mice. 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
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Table 2: Static and Dynamic Trabecular Bone Parameters in bGH Mice Tibiae Compared With NT 614 
Tibiae 615 
Histomorphometry 
Parameters NT bGH 
BV/TV, % 14.225 
± 1.549 
8.490 ± 
2.867a 
Tb.N, 1/mm 3.440 ± 
0.582 
2.380 ± 
0.673 
Tb.Th, mm 0.042 ± 
0.009 
0.035 ± 
0.003 
Tb.Sp, mm 0.255 ± 
0.042 
0.412 ± 
0.150a 
MS/BS, % 24.34 ± 
6.49 
40.54 ± 
8.34a 
MAR, μm/d 1.546 ± 
0.413 
2.329 ± 
0.290a 
BFR/BS, μm3/μm2/d 0.387 ± 
0.189 
1.001 ± 
0.163a 
Oc.S/BS, μm 6.623 ± 
1.038 
9.895 ± 
0.306a 
Oc.N/BS, 1/mm 2.19 ± 
0.54 
2.82 ± 
0.46 
 616 
Mean ± SD (five and six mice per group). 617 
aP < .05 vs NT.  618 
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Table 3: Trabecular and Cortical Bone Parameters in Vertebrae of NT and bGH Mice Aged 5 Months 619 
 620 
 
NT Mice bGH Mice Results Expressed as a Ratio of Vertebrae Length 
NT mice bGH Mice 
BV/TV, % 5.699 ± 1.120 6.151 ± 1.294 1.718 ± 0.323 1.409 ± 0.286a 
Tb.N, 1/mm 1.578 ± 0.173 2.077 ± 0.357b 0.476 ± 0.049 0.475 ± 0.072 
Tb.Th, mm 0.035 ± 0.004 0.029 ± 0.001b 0.011 ± 0.001 0.006 ± 0.001b 
Tb.Sp, mm 0.418 ± 0.026 0.462 ± 0.055a 0.126 ± 0.009 0.105 ± 0.010b 
TBPf, 1/mm −1.515 ± 4.94 −6.590 ± 6.951 −0.446 ± 1.512 −1.454 ± 1.544 
SMI 0.739 ± 0.274 0.697 ± 0.235 0.224 ± 0.087 0.161 ± 0.058 
DA 1.898 ± 0.544 1.604 ± 0.233a 0.572 ± 0.154 0.368 ± 0.054b 
Tt.Ar, mm2 0.428 ± 0.017 0.478 ± 0.177 0.129 ± 0.035 0.109 ± 0039 
Cs.Ar, mm2 0.278 ± 0.027 0.326 ± 0.061b 0.084 ± 0.007 0.074 ± 0.010a (N) 
Cs.Pm, mm 12.23 ± 0.632 17.60 ± 2.576c 3.698 ± 0.210 4.017 ± 0.357 
Cs.Th, mm 0.045 ± 0.003 0.036 ± 0.003c 0.013 ± 0.001 0.008 ± 0.001c 
Ma.Ar, mm2 0.149 ± 0.100 1.152 ± 0.090 0.045 ± 0.030 0.034 ± 0.031 
 621 
Abbreviation: N, nonsignificant after adjustment by body weight. 622 
aP < .05 vs NT mice. 623 
bP < .01 vs NT mice. 624 
cP < .0001 vs NT mice. 625 
 626 
 627 
 628 
Table 4: Static and Dynamic Trabecular Bone Parameters in bGH Mice Vertebrae Compared With NT 629 
Vertebrae 630 
 631 
Histomorphometry 
Parameters NT bGH 
BV/TV, % 16.532 ± 3.291 15.198 ± 2.766 
Tb.N, 1/mm 4.571 ± 0.451 4.754 ± 0.837 
Tb.Th, mm 0.036 ± 0.004 0.032 ± 0.004 
Tb.Sp, mm 0.184 ± 0.025 0.185 ± 0.043 
MS/BS, % 38.70 ± 2.869 55.60 ± 4.375a 
MAR, μm/d 2.081 ± 0.155 3.139 ± 0.175a 
BFR/BS, μm3/μm2/d 0.808 ± 0.116 1.719 ± 0.191a 
 632 
Mean ± SD (seven to nine mice per group). 633 
aP < .01 vs NT. 634 
